Zenas BioPharma appoints Orlando Oliveira as Chief Commercial Officer to drive obexelimab growth.
Zenas BioPharma, an immunology-based therapy company, has appointed Orlando Oliveira as Chief Commercial Officer. Oliveira brings 25 years of experience in the biotech and pharma industry, with a record of building global commercial teams and driving revenue growth. His appointment aims to accelerate the obexelimab franchise and support Zenas' goal to bring obexelimab to patients worldwide.
July 01, 2024
3 Articles